67. Polycystic kidney disease
186 clinical trials, 196 drugs (DrugBank: 47 drugs), 35 drug target genes, 146 drug target pathways
Searched query = "Polycystic kidney disease", "PKD", "PCKD", "Polycystic kidney", "ADPKD", "ARPKD"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04064346 (ClinicalTrials.gov) | July 2021 | 19/8/2019 | Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease | A 52-Week, Phase 3, Double-blind, Placebo-controlled, Randomized Study of the Efficacy and Safety of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Polycystic Kidney Disease, Adult | Drug: Lixivaptan;Drug: Placebo | Palladio Biosciences | NULL | Not yet recruiting | 18 Years | 60 Years | All | 1200 | Phase 3 | NULL |
| 2 | NCT04578548 (ClinicalTrials.gov) | November 10, 2020 | 1/10/2020 | A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | An Exploratory, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Orally Administered GLPG2737 for 52 Weeks, in Subjects With Autosomal Dominant Polycystic Kidney Disease | Autosomal Dominant Polycystic Kidney Disease | Drug: GLPG2737;Drug: Placebo | Galapagos NV | NULL | Recruiting | 18 Years | 50 Years | All | 60 | Phase 2 | Belgium;Germany;Netherlands;Poland;Spain |
| 3 | NCT04407481 (ClinicalTrials.gov) | November 1, 2020 | 19/5/2020 | PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN) | PENGUIN: PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD | Polycystic Kidney Disease, Adult;Polycystic Kidney, Autosomal Dominant | Drug: Aminohippurate Sodium Inj 20%;Drug: Iohexol Inj 300 milligrams per milliliter (MG/ML);Radiation: PET/CT Scan | University of Colorado Denver School of Medicine Barbara Davis Center | NULL | Recruiting | 18 Years | 40 Years | All | 20 | United States | |
| 4 | NCT04536688 (ClinicalTrials.gov) | October 2020 | 24/8/2020 | A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease | A Phase 1b, Multicenter, Open-Label, Adaptive Design Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RGLS4326 Administered Via SC Injection to Patients With Autosomal Dominant Polycystic Kidney Disease | Polycystic Kidney Disease, Autosomal Dominant | Drug: RGLS4326 | Regulus Therapeutics Inc. | NULL | Recruiting | 18 Years | 70 Years | All | 27 | Phase 1 | United States |
| 5 | NCT04310319 (ClinicalTrials.gov) | September 7, 2020 | 3/3/2020 | Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt | Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt | Polycystic Kidney, Autosomal Dominant;ADPKD;Autosomal Dominant Polycystic Kidney | Dietary Supplement: Sodiumchloride;Dietary Supplement: Protein;Dietary Supplement: Placebo comparator (salt);Dietary Supplement: Placebo comparator (protein) | Esther Meijer | NULL | Recruiting | 18 Years | N/A | All | 12 | N/A | Netherlands |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT04152837 (ClinicalTrials.gov) | September 2, 2020 | 31/10/2019 | Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease | An Open-Label Study of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Previously Experienced Abnormal Liver Chemistry Test Results While Receiving Tolvaptan: The ALERT Study | Polycystic Kidney Disease, Adult | Drug: Lixivaptan | Palladio Biosciences | NULL | Recruiting | 18 Years | 65 Years | All | 50 | Phase 3 | United States |
| 7 | NCT03949894 (ClinicalTrials.gov) | July 1, 2019 | 16/4/2019 | Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease | Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Drug: Tolvaptan | Korea Otsuka Pharmaceutical Co., Ltd. | NULL | Active, not recruiting | 19 Years | 50 Years | All | 118 | Phase 4 | Korea, Republic of |
| 8 | NCT03918447 (ClinicalTrials.gov) | May 29, 2019 | 12/4/2019 | A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON | A Phase 3 Trial of Bardoxolone Methyl in Patients With Autosomal Dominant Polycystic Kidney Disease | Autosomal Dominant Polycystic Kidney;ADPKD | Drug: Bardoxolone methyl oral capsule;Drug: Placebo oral capsule | Reata Pharmaceuticals, Inc. | NULL | Recruiting | 18 Years | 70 Years | All | 300 | Phase 3 | United States;Australia;Belgium;Czechia;France;Germany;Italy;Japan;Spain;United Kingdom |
| 9 | NCT03717181 (ClinicalTrials.gov) | May 22, 2019 | 22/10/2018 | Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease | Expanded Access Use of Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease | Polycystic Kidney | Drug: Lixivaptan | Palladio Biosciences | NULL | Active, not recruiting | 15 Years | 60 Years | All | 1 | Phase 2 | United States |
| 10 | NCT03749447 (ClinicalTrials.gov) | March 8, 2019 | 19/11/2018 | An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) | An Extended Access Program to Assess Long Term Safety of Bardoxolone Methyl in Patients With Chronic Kidney Disease | Chronic Kidney Diseases;Alport Syndrome;Autosomal Dominant Polycystic Kidney | Drug: Bardoxolone methyl | Reata Pharmaceuticals, Inc. | NULL | Recruiting | 12 Years | N/A | All | 480 | Phase 3 | United States;Australia;Japan;Puerto Rico |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT03764605 (ClinicalTrials.gov) | January 30, 2019 | 29/11/2018 | Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease | Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease. A Phase 3a, Indipendent, Multicentre, Two Parallel Arms, Randomized Controlled Trial | ADPKD | Drug: Metformin;Drug: Tolvaptan | Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari | NULL | Not yet recruiting | 18 Years | 50 Years | All | 150 | Phase 3 | Italy |
| 12 | NCT04284657 (ClinicalTrials.gov) | January 30, 2019 | 11/4/2019 | Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease | Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease | Autosomal Dominant Polycystic Kidney Disease | Drug: Pravastatin;Drug: sodium citrate | University of Southern California | NULL | Recruiting | 18 Years | N/A | All | 30 | Phase 2 | United States |
| 13 | NCT03541447 (ClinicalTrials.gov) | December 12, 2018 | 17/5/2018 | Tolvaptan-Octreotide LAR Combination in ADPKD | A Pilot, Phase II Study With a Prospective, Randomized, Cross-Over, Placebo-Controlled, Double-Blind Design to Assess the Short-Term Effects of Tolvaptan Plus Placebo vs Tolvaptan Plus Octreotide LAR Combination Therapy in ADPKD Patients With Normal Kidney Function or Hyperfiltration | Autosomal Dominant Polycystic Kidney Disease | Drug: Tolvaptan;Drug: Octreotide LAR;Other: Placebo | Mario Negri Institute for Pharmacological Research | Otsuka Pharmaceutical Italy S.r.l. | Recruiting | 18 Years | N/A | All | 20 | Phase 2 | Italy |
| 14 | EUCTR2018-000477-77-IT (EUCTR) | 08/11/2018 | 04/11/2020 | Evaluation of Metformin and Tolvaptan in slowing disease progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Metformin versus Tolvaptan in adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD): a phase 3a, independent, multi-centre, 2 parallel arms randomized controlled trial - METROPOLIS | Autosomal Dominant Polycystic Kidney Disease MedDRA version: 20.0;Level: LLT;Classification code 10036046;Term: Polycystic kidney, autosomal dominant;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: ZUGLIMET - 500 MG COMPRESSE RIVESTITE CON FILM 30 COMPRESSE IN BLISTER PVC/AL Product Name: METFORMINA Product Code: [METFORMINA] INN or Proposed INN: METFORMINA Other descriptive name: METFORMIN Trade Name: JINARC - 15 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE Product Name: TOLVAPTAN 15 Product Code: [TOLVAPTAN 15] INN or Proposed INN: TOLVAPTAN Other descriptive name: TOLVAPTAN Trade Name: JINARC - 30 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE Product Name: TOLVAPTAN 30 Product Code: [TOLVAPTAN 30] INN or Proposed INN: TOLVAPTAN Other descriptive name: TOLVAPTAN Trade Name: JINARC - 15 MG +45 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28X15 MG + 28 X 45 MG) Product Name: TOLVAPTAN 45/15 Product Code: [TOLVAPTAN 45/15] INN or Proposed INN: TOLVAPTAN Other descriptive name: TOLVAPTAN Trade Name: JINARC - 30 MG + 60 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 60 MG) Product Name: TOLVAPTAN 60/30 Product Code: [TOL | U.O. NEFROLOGIA, DIALISI E TRAPIANTO AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO DI BARI | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 150 | Phase 3 | Italy | ||
| 15 | NCT03687554 (ClinicalTrials.gov) | October 5, 2018 | 26/9/2018 | Effect of Venglustat in Patients With Renal Impairment | A Phase I, Single-Center, Open-label, Single Dose Pharmacokinetic and Tolerability Study of GZ402671 in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function | Healthy Volunteers;Polycystic Kidney, Autosomal Dominant | Drug: Venglustat GZ/SAR402671 | Genzyme, a Sanofi Company | NULL | Completed | 18 Years | 79 Years | All | 24 | Phase 1 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT03523728 (ClinicalTrials.gov) | October 4, 2018 | 1/5/2018 | A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients | Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at Risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Polycystic Kidney, Autosomal Dominant | Drug: Venglustat GZ402671;Drug: Placebo | Genzyme, a Sanofi Company | NULL | Recruiting | 18 Years | 55 Years | All | 640 | Phase 2;Phase 3 | United States;Argentina;Australia;Austria;Belgium;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Taiwan;United Kingdom |
| 17 | NCT03487913 (ClinicalTrials.gov) | September 14, 2018 | 16/3/2018 | The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease | A Phase 2, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease | Autosomal Dominant Polycystic Kidney Disease | Drug: Lixivaptan | Palladio Biosciences | NULL | Completed | 18 Years | 65 Years | All | 31 | Phase 2 | United States |
| 18 | NCT03596957 (ClinicalTrials.gov) | September 12, 2018 | 14/2/2018 | Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease | Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease | Autosomal Dominant Polycystic Kidney | Drug: Tolvaptan | Lisbet Brandi | NULL | Unknown status | 18 Years | 65 Years | All | 90 | Phase 4 | Denmark |
| 19 | NCT03423810 (ClinicalTrials.gov) | April 23, 2018 | 31/1/2018 | Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients | Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients | Polycystic Kidney Diseases | Drug: Hydralazine | University of Kansas Medical Center | NULL | Completed | 18 Years | 65 Years | All | 14 | Early Phase 1 | United States |
| 20 | NCT03366337 (ClinicalTrials.gov) | December 26, 2017 | 4/12/2017 | A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX | A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases | IgA Nephropathy;CKD Associated With Type 1 Diabetes;Focal Segmental Glomerulosclerosis;Autosomal Dominant Polycystic Kidney | Drug: Bardoxolone methyl capsules | Reata Pharmaceuticals, Inc. | NULL | Completed | 18 Years | 65 Years | All | 103 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT03273413 (ClinicalTrials.gov) | August 31, 2017 | 1/9/2017 | Statin Therapy in Patients With Early Stage ADPKD | Statin Therapy in Patients With Early Stage ADPKD | ADPKD;Autosomal Dominant Polycystic Kidney | Drug: Pravastatin;Drug: Placebo | University of Colorado, Denver | NULL | Recruiting | 25 Years | 60 Years | All | 200 | Phase 4 | United States |
| 22 | NCT03203642 (ClinicalTrials.gov) | August 9, 2017 | 26/6/2017 | Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD | A Double-blind Randomized Parallel Group Study of the Efficacy and Safety of Tesevatinib in Subjects With Autosomal Dominant Polycystic Kidney Disease | Autosomal Dominant Polycystic Kidney;ADPKD | Drug: Tesevatinib;Drug: Placebo | Kadmon Corporation, LLC | NULL | Active, not recruiting | 18 Years | 60 Years | All | 80 | Phase 2 | United States |
| 23 | NCT03096080 (ClinicalTrials.gov) | June 14, 2017 | 6/3/2017 | A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD) | A Phase 1, Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD) | Polycystic Kidney, Autosomal Recessive | Drug: Tesevatinib | Kadmon Corporation, LLC | NULL | Completed | 5 Years | 12 Years | All | 10 | Phase 1 | United States |
| 24 | NCT03102632 (ClinicalTrials.gov) | June 1, 2017 | 27/3/2017 | A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease | A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease | Autosomal Dominant Polycystic Kidney | Other: High Water Intake | The Rogosin Institute | Weill Medical College of Cornell University | Recruiting | 18 Years | 65 Years | All | 32 | N/A | United States |
| 25 | NCT02903511 (ClinicalTrials.gov) | November 2016 | 13/9/2016 | Feasibility Study of Metformin Therapy in ADPKD | Feasibility Study of Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease. | Polycystic Kidney, Autosomal Dominant | Drug: Metformin;Drug: Placebo | University of Colorado, Denver | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | 30 Years | 60 Years | All | 52 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT02729662 (ClinicalTrials.gov) | October 1, 2016 | 11/3/2016 | Efficacy of Tolvaptan on ADPKD Patients | Longitudinal Efficacy and Safety Study of Tolvaptan on Autosomal Dominant Polycystic Kidney Disease Patients (LET-PKD Study) | Autosomal Dominant Polycystic Kidney Disease | Drug: Tolvaptan | Kyorin University | NULL | Active, not recruiting | 18 Years | N/A | All | 118 | N/A | Japan |
| 27 | NCT02933268 (ClinicalTrials.gov) | September 26, 2016 | 18/9/2016 | High Water Intake in Polycystic Kidney Disease | Determining Feasibility of Randomisation to High vs ad Libitum Water Intake in Polycystic Kidney Disease: The DRINK Randomised Feasibility Trial | Autosomal Dominant Polycystic Kidney Disease | Dietary Supplement: High water intake;Other: Ad libitum water intake | Cambridge University Hospitals NHS Foundation Trust | PKD Charity;Addenbrookes Charitable Trust;British Renal Society & British Kidney Patient Association | Completed | 16 Years | N/A | All | 42 | N/A | United Kingdom |
| 28 | NCT02964273 (ClinicalTrials.gov) | September 2016 | 15/9/2016 | Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease) | A Phase 3b, Two-part, Multicenter, One Year Randomized, Double-blind, Placebo-controlled Trial of the Safety, Pharmacokinetics, Tolerability, and Efficacy of Tolvaptan Followed by a Two Year Open-label Extension in Children and Adolescent Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Drug: Tolvaptan;Drug: Matching Placebo | Otsuka Pharmaceutical Development & Commercialization, Inc. | NULL | Active, not recruiting | 4 Years | 17 Years | All | 91 | Phase 3 | Belgium;Germany;Italy;United Kingdom |
| 29 | NCT03406286 (ClinicalTrials.gov) | July 19, 2016 | 22/12/2017 | Samsca PMS in ADPKD Patients | Post-Marketing Surveillance(PMS) of Safety and Efficacy of Samsca® Tablets in Korean Patients With ADPKD | Safety | Drug: Tolvaptan | Korea Otsuka Pharmaceutical Co., Ltd. | NULL | Recruiting | 18 Years | N/A | All | 600 | Korea, Republic of | |
| 30 | NCT02656017 (ClinicalTrials.gov) | June 27, 2016 | 23/12/2015 | Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease | Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease | Polycystic Kidney, Autosomal Dominant | Drug: Metformin;Other: Placebo | Kyongtae Ty Bae, M.D., Ph.D. | Tufts Medical Center;University of Maryland, Baltimore;University of Southern California;United States Department of Defense | Active, not recruiting | 18 Years | 60 Years | All | 97 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | NCT02697617 (ClinicalTrials.gov) | January 26, 2016 | 30/10/2015 | Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease | Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney | Polycystic Kidney Disease | Drug: Pioglitazone;Drug: Placebo | Indiana University | NULL | Active, not recruiting | 18 Years | 55 Years | All | 18 | Phase 2 | United States |
| 32 | NCT03803124 (ClinicalTrials.gov) | December 2015 | 7/1/2019 | Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD | Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD | Polycystic Kidney, Autosomal Dominant | Drug: Tolvaptan;Drug: Placebo | Regional Hospital Holstebro | NULL | Completed | 18 Years | N/A | All | 20 | Phase 3 | Denmark |
| 33 | NCT02616055 (ClinicalTrials.gov) | December 2015 | 24/11/2015 | Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 | Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 in Subjects With Autosomal Dominant Polycystic Kidney Disease | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Drug: tesevatinib | Kadmon Corporation, LLC | NULL | Terminated | 18 Years | 55 Years | All | 15 | Phase 2 | United States |
| 34 | NCT02494141 (ClinicalTrials.gov) | November 12, 2015 | 25/6/2015 | Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD | Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD | Polycystic Kidney, Autosomal Dominant | Drug: Curcumin;Other: Placebo | University of Colorado, Denver | NULL | Active, not recruiting | 6 Years | 25 Years | All | 68 | Phase 4 | United States |
| 35 | NCT02558595 (ClinicalTrials.gov) | September 22, 2015 | 21/9/2015 | Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2) | Randomized, Controlled Pilot Study of Niacinamide in Polycystic Kidney Disease | Polycystic Kidney Disease | Dietary Supplement: Niacinamide;Other: Placebo | University of Kansas Medical Center | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | 18 Years | 60 Years | All | 36 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | NCT02776241 (ClinicalTrials.gov) | September 2015 | 4/5/2016 | Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease | Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney: The HYDRA Study | ADPKD | Other: water | Rigshospitalet, Denmark | Aarhus University Hospital | Completed | 18 Years | N/A | All | 40 | N/A | Denmark |
| 37 | NCT02527863 (ClinicalTrials.gov) | February 2015 | 18/2/2015 | Effect of the Aquaretic Tolvaptan on Nitric Oxide System | The Effects of Tolvaptan on Renal Handling of Water and Sodium, Vasoactive Hormones and Central Hemodynamics During Baseline Conditions and After Inhibition of the Nitric Oxide System in Patients With Autosomal Dominant Polycystic Kidney Disease | Autosomal Dominant Polycystic Kidney Disease | Drug: Tolvaptan;Drug: Placebo | Regional Hospital Holstebro | Aarhus University Hospital | Completed | 18 Years | 65 Years | All | 18 | Phase 2 | Denmark |
| 38 | NCT02251275 (ClinicalTrials.gov) | October 17, 2014 | 25/9/2014 | Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease | A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Immediate-release Tolvaptan (OPC-41061, 30 mg to 120 mg/Day, Split Dose) in Subjects With Autosomal Dominant Polycystic Kidney Disease | Polycystic Kidney, Autosomal Dominant | Drug: Tolvaptan | Otsuka Pharmaceutical Development & Commercialization, Inc. | NULL | Completed | 18 Years | N/A | All | 1803 | Phase 3 | United States;Argentina;Australia;Belgium;Canada;Czechia;Denmark;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;United Kingdom;Czech Republic |
| 39 | NCT02134899 (ClinicalTrials.gov) | October 14, 2014 | 28/4/2014 | The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients | An Open-labelled Multicenter Randomized Study on the Efficacy of Everolimus in Reducing Total Native Kidney Volume in Kidney Transplanted Patients With Autosomal Dominant Polycystic Kidney Disease | Autosomal Dominant Polycystic Kidney Disease | Drug: Everolimus;Drug: Calcineurin inhibitors maintenance | Assistance Publique - Hôpitaux de Paris | Novartis | Completed | 18 Years | 75 Years | All | 3 | Phase 3 | France |
| 40 | NCT02127437 (ClinicalTrials.gov) | September 19, 2014 | 2/4/2014 | Lanreotide In Polycystic Kidney Disease Study | Lanreotide In Polycystic Kidney Disease Study | Autosomal Dominant Polycystic Kidney Disease (ADPKD | Drug: Lanreotide;Drug: saline | Assistance Publique - Hôpitaux de Paris | IPSEN pharmaceutical company, Boulogne-Billancourt, France | Completed | 18 Years | N/A | All | 159 | Phase 3 | France |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | NCT02160145 (ClinicalTrials.gov) | May 2014 | 6/6/2014 | Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease | A Phase 3b, Multi-center, Randomized-withdrawal, Placebo-controlled, Double-blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45 to 120 mg/Day, Split-dose) in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease | Chronic Kidney Disease;Autosomal Dominant Polycystic Kidney Disease | Drug: Tolvaptan (OPC-41061);Drug: Placebo | Otsuka Pharmaceutical Development & Commercialization, Inc. | NULL | Completed | 18 Years | 65 Years | All | 1370 | Phase 3 | United States;Argentina;Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Puerto Rico;Romania;Russian Federation;South Africa;Spain;Sweden;United Kingdom;Czech Republic |
| 42 | NCT02225860 (ClinicalTrials.gov) | May 2014 | 20/8/2014 | Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease | Low Osmolar Diet and Adjusted Water Intake for Vasopressin Suppression in ADPKD | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Behavioral: Diet and water adjustment | Tufts Medical Center | NULL | Completed | 18 Years | 60 Years | All | 34 | Phase 2;Phase 3 | United States |
| 43 | NCT02140814 (ClinicalTrials.gov) | May 2014 | 14/5/2014 | Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease | Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease | Polycystic Kidney Disease | Dietary Supplement: Niacinamide | Alan Yu, MB, BChir | NULL | Completed | 18 Years | 50 Years | Both | 10 | Phase 2 | United States |
| 44 | NCT02055079 (ClinicalTrials.gov) | April 2014 | 31/1/2014 | Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease | Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease - The Vienna RAP Study | Polycystic Kidney, Type 1 Autosomal Dominant Disease;Polycystic Kidney, Type 2 Autosomal Dominant Disease | Drug: Sirolimus;Drug: Placebo | Medical University of Vienna | NULL | Unknown status | 18 Years | N/A | All | 68 | Phase 3 | Austria |
| 45 | NCT02847624 (ClinicalTrials.gov) | March 2014 | 25/7/2016 | Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD | Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD in Japan | Polycystic Kidney, Autosomal Dominant | Drug: tolvaptan | Otsuka Pharmaceutical Co., Ltd. | NULL | Recruiting | N/A | N/A | All | 1600 | Japan | |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | NCT01853553 (ClinicalTrials.gov) | July 2013 | 8/5/2013 | Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney | ADPKD | Drug: Spironolactone;Drug: Sugar pill | University of Colorado, Denver | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | 20 Years | 55 Years | All | 61 | Phase 3 | United States |
| 47 | NCT01559363 (ClinicalTrials.gov) | September 2012 | 9/3/2012 | A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD | A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Polycystic Kidney, Autosomal Dominant | Drug: KD019 (tesevatinib) | Kadmon Corporation, LLC | NULL | Completed | 22 Years | 62 Years | All | 74 | Phase 1;Phase 2 | United States |
| 48 | NCT01670110 (ClinicalTrials.gov) | August 2012 | 17/8/2012 | Pasireotide LAR in Severe Polycystic Liver Disease | A Randomized, Placebo Controlled Clinical Trial of SOM230 (Pasireotide LAR) In Severe Polycystic Liver Disease | Somatostatin Analogs;Polycystic Liver Disease;Autosomal Dominant Polycystic Kidney Disease;Autosomal Dominant Polycystic Liver Disease | Drug: Pasireotide LAR;Drug: Placebo | Mayo Clinic | NULL | Completed | 18 Years | 100 Years | All | 48 | Phase 2 | United States |
| 49 | NCT01616927 (ClinicalTrials.gov) | June 2012 | 6/6/2012 | Study of Lanreotide to Treat Polycystic Kidney Disease | The DIPAK 1 Study: A Randomised, Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in ADPKD | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Drug: Lanreotide | University Medical Center Groningen | Leiden University Medical Center;Erasmus Medical Center;Radboud University | Active, not recruiting | 18 Years | 60 Years | All | 300 | Phase 3 | Netherlands |
| 50 | NCT01451827 (ClinicalTrials.gov) | October 2011 | 11/10/2011 | 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) | A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind, Placebo-masked, Parallel-group Pilot Trial to Compare the Efficacy, Tolerability, and Safety of Tolvaptan Modified-release and Immediate-release Formulations in Subjects With Autosomal Dominant Polycystic Kidney Disease | Autosomal Dominant Polycystic Kidney Disease | Drug: Tolvaptan MR;Drug: Tolvaptan IR;Drug: Placebo | Otsuka Pharmaceutical Development & Commercialization, Inc. | NULL | Completed | 18 Years | 50 Years | All | 178 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 51 | NCT01377246 (ClinicalTrials.gov) | May 2011 | 20/6/2011 | Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency | A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL TO ASSESS THE EFFECTS OF LONG-ACTING SOMATOSTATIN (OCTREOTIDE LAR) THERAPY ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND MODERATE TO SEVERE RENAL INSUFFICIENCY | Autosomal Dominant Polycystic Kidney Disease | Drug: Octreotide-LAR;Other: Saline solution. | Mario Negri Institute for Pharmacological Research | NULL | Completed | 18 Years | 75 Years | All | 100 | Phase 3 | Italy |
| 52 | EUCTR2011-000138-12-IT (EUCTR) | 04/04/2011 | 28/12/2011 | A prospective, randomized, double-blind, placebo controlled clinical trial to assess the effects of long-acting somatostatin (Octreotide LAR)therapy on disease progression in patients with Autosomal Dominant Polycystic Kidney Disease and moderate to severe renal insufficiency - ALADIN 2 | A prospective, randomized, double-blind, placebo controlled clinical trial to assess the effects of long-acting somatostatin (Octreotide LAR)therapy on disease progression in patients with Autosomal Dominant Polycystic Kidney Disease and moderate to severe renal insufficiency - ALADIN 2 | Autosomal Dominant Polycystic Kidney Disease MedDRA version: 14.1;Level: LLT;Classification code 10036046;Term: Polycystic kidney, autosomal dominant;System Organ Class: 10010331 - Congenital, familial and genetic disorders | IST. DI RICERCHE FARMACOLOG. M. NEGRI | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 3 | Italy | |||
| 53 | EUCTR2010-023017-65-ES (EUCTR) | 18/03/2011 | 27/01/2011 | ESTUDIO EN FASE 2, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO DE LA SEGURIDAD, LA ACTIVIDAD CLÍNICA Y LA FARMACOCINÉTICA DE BOSUTINIB (PF-05208763) FRENTE A PLACEBO EN SUJETOS CON POLIQUISTOSIS RENAL AUTOSÓMICA DOMINANTE (PRAD). - A Phase 2, multicenter, randomized, double-blind, placebo-controlled study of the safety, clinical activity and pharmacokinetics of bosutinib (PF-05208763) versus placebo in subjects with autosomal dominant polycystic kidney disease (ADPKD). | ESTUDIO EN FASE 2, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO DE LA SEGURIDAD, LA ACTIVIDAD CLÍNICA Y LA FARMACOCINÉTICA DE BOSUTINIB (PF-05208763) FRENTE A PLACEBO EN SUJETOS CON POLIQUISTOSIS RENAL AUTOSÓMICA DOMINANTE (PRAD). - A Phase 2, multicenter, randomized, double-blind, placebo-controlled study of the safety, clinical activity and pharmacokinetics of bosutinib (PF-05208763) versus placebo in subjects with autosomal dominant polycystic kidney disease (ADPKD). | Poliquistosis renal autosómica dominante (PRAD). MedDRA version: 12.1;Level: LLT;Classification code 10036046;Term: Polycystic kidney, autosomal dominant | Product Name: Bosutinib Product Code: PF-05208763 INN or Proposed INN: Bosutinib (anhydrous) Other descriptive name: SKI-606 | PFIZER, S.L.U. | NULL | Not Recruiting | Female: yes Male: yes | 275 | Phase 2 | Hungary;Czech Republic;Slovakia;Poland;Spain;Lithuania;Italy;United Kingdom;Sweden | ||
| 54 | NCT01233869 (ClinicalTrials.gov) | December 2010 | 28/10/2010 | Bosutinib For Autosomal Dominant Polycystic Kidney Disease | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Polycystic Kidney, Autosomal Dominant | Drug: Bosutinib;Drug: Placebo | Pfizer | NULL | Completed | 18 Years | 50 Years | All | 172 | Phase 2 | United States;Australia;Canada;Czech Republic;Hungary;Italy;Korea, Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom |
| 55 | NCT01280721 (ClinicalTrials.gov) | November 2010 | 6/12/2010 | A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan] | A Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan] | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Drug: tolvaptan | Otsuka Pharmaceutical Co., Ltd. | NULL | Completed | 23 Years | 53 Years | All | 135 | Phase 3 | Japan |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 56 | NCT01210560 (ClinicalTrials.gov) | October 2010 | 21/9/2010 | Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD | A Multi-center, Parallel-group, Randomized, Double-blind, Placebo-masked, Multiple Dose Trial of Modified-release (MR) and Immediate-release (IR) Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Autosomal Dominant Polycystic Kidney Disease | Drug: Tolvaptan MR;Drug: Tolvaptan IR | Otsuka Pharmaceutical Development & Commercialization, Inc. | NULL | Completed | 18 Years | 50 Years | All | 25 | Phase 2 | United States |
| 57 | NCT01336972 (ClinicalTrials.gov) | October 2010 | 15/4/2011 | Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | A Phase 2a, Single-center Study Investigating the Short-term Renal Hemodynamic Effects, Safety and Pharmacokinetics/ Pharmacodynamics of Oral Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease at Various Stages of Renal Function | Autosomal Dominant Polycystic Kidney Disease | Drug: Tolvaptan | Otsuka Pharmaceutical Development & Commercialization, Inc. | NULL | Completed | 18 Years | 70 Years | All | 29 | Phase 2 | Netherlands |
| 58 | NCT01214421 (ClinicalTrials.gov) | May 2010 | 26/9/2010 | Open-Label Tolvaptan Study in Subjects With ADPKD | Multi-center, Open-label, Extension Study to Evaluate the Long-term Efficacy and Safety of Oral Tolvaptan Tablet Regimens in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Drug: Tolvaptan | Otsuka Pharmaceutical Development & Commercialization, Inc. | NULL | Completed | 18 Years | N/A | All | 1083 | Phase 3 | United States;Argentina;Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom |
| 59 | EUCTR2009-012376-27-IT (EUCTR) | 16/11/2009 | 30/11/2009 | EFFECTS OF LONG-ACTING SOMATOSTATIN ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND MODERATE/SEVERE RENAL INSUFFICIENCY(ALADIN II STUDY) - ALADIN II | EFFECTS OF LONG-ACTING SOMATOSTATIN ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND MODERATE/SEVERE RENAL INSUFFICIENCY(ALADIN II STUDY) - ALADIN II | Polycystic Kidney MedDRA version: 12.1;Level: LLT;Classification code 10036046;Term: Polycystic kidney, autosomal dominant | Trade Name: SANDOSTATINA LAR INN or Proposed INN: Octreotide | IST. DI RICERCHE FARMACOLOG. M. NEGRI | NULL | Not Recruiting | Female: yes Male: yes | Italy | ||||
| 60 | NCT01022424 (ClinicalTrials.gov) | November 2009 | 27/11/2009 | A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002] | A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002] | Autosomal Dominant Polycystic Kidney Disease | Drug: OPC-41061 | Otsuka Pharmaceutical Co., Ltd. | NULL | Completed | N/A | N/A | All | 13 | Phase 3 | Japan |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 61 | NCT00920309 (ClinicalTrials.gov) | June 2009 | 12/6/2009 | Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy | Rapamycin as Treatment for ADPKD: The Role of Biomarkers in Predicting a Response to Therapy | Autosomal Dominant Polycystic Kidney Disease | Drug: Rapamycin;Other: Standard of Care-Placebo | Yale University | NULL | Terminated | 18 Years | 70 Years | All | 21 | Phase 2;Phase 3 | United States |
| 62 | NCT00784030 (ClinicalTrials.gov) | November 2008 | 31/10/2008 | High Water Intake to Slow Progression of Polycystic Kidney Disease | The Effect of Water Loading on Urinary Biomarkers | Kidney, Polycystic, Autosomal Dominant | Other: Water | New York University School of Medicine | NULL | Completed | 18 Years | 65 Years | All | 23 | N/A | United States |
| 63 | NCT00428948 (ClinicalTrials.gov) | January 2007 | 26/1/2007 | Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) | A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablets Regimens in Adult Subjects With Autosomal Dominant Polycystic Kidney Disease | Polycystic Kidney Disease, Autosomal Dominant | Drug: Tolvaptan;Drug: Placebo | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Pharmaceutical Co., Ltd. | Completed | 18 Years | 50 Years | All | 1445 | Phase 3 | United States;Argentina;Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;United Kingdom |
| 64 | NCT00426153 (ClinicalTrials.gov) | January 2007 | 22/1/2007 | Octreotide in Severe Polycystic Liver Disease | Pilot Study Of Long-Acting Octreotide (Octreotide LAR® Depot) In The Treatment Of Patients With Severe Polycystic Liver Disease | Polycystic Kidney, Autosomal Dominant;Polycystic Liver Disease;Hepatomegaly;Liver Diseases;Kidney, Polycystic;Abdominal Pain | Drug: Octreotide;Drug: Placebo | Mayo Clinic | Novartis;National Center for Research Resources (NCRR) | Completed | 18 Years | 80 Years | All | 42 | Phase 2;Phase 3 | United States |
| 65 | NCT00414440 (ClinicalTrials.gov) | December 2006 | 20/12/2006 | Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease | A Multicenter, Randomized, Placebo-controlled, Double-blind Study on the Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease (ESRD) in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Autosomal Dominant Polycystic Kidney Disease | Drug: Placebo;Drug: Everolimus | Novartis Pharmaceuticals | NULL | Completed | 18 Years | 50 Years | All | 431 | Phase 4 | Austria;France;Germany |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 66 | NCT00456365 (ClinicalTrials.gov) | November 2006 | 12/3/2007 | Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease | Polycystic Kidney, Autosomal Dominant | Drug: pravastatin;Drug: Placebo | University of Colorado, Denver | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | 8 Years | 22 Years | All | 110 | Phase 3 | United States |
| 67 | NCT00286156 (ClinicalTrials.gov) | October 2006 | 1/2/2006 | Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease | Polycystic Kidney Diseases | Drug: Rapamune | The Cleveland Clinic | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | 18 Years | 75 Years | All | 30 | Phase 1;Phase 2 | United States |
| 68 | NCT00841568 (ClinicalTrials.gov) | April 2006 | 9/2/2009 | A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001] | A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001] | Autosomal Dominant Polycystic Kidney Disease | Drug: OPC-41061 | Otsuka Pharmaceutical Co., Ltd. | NULL | Completed | N/A | N/A | All | 17 | Phase 2 | Japan |
| 69 | EUCTR2005-005552-41-IT (EUCTR) | 20/02/2006 | 06/03/2007 | Effect of long-acting somatostatin on disease progression in nephropathy due to autosomal dominant polycystic disease a long-term three year follow-up study - ALADIN | Effect of long-acting somatostatin on disease progression in nephropathy due to autosomal dominant polycystic disease a long-term three year follow-up study - ALADIN | Autosomal Dominant Polycystic Kidney Disease ADPKD MedDRA version: 6.1;Level: SOC;Classification code 10038359 | IST. DI RICERCHE FARMACOLOG. M. NEGRI | NULL | Not Recruiting | Female: yes Male: yes | 66 | Phase 3 | Italy | |||
| 70 | NCT00283686 (ClinicalTrials.gov) | January 2006 | 26/1/2006 | HALT Progression of Polycystic Kidney Disease Study A | HALT Progression of Polycystic Kidney Disease Study A | Kidney, Polycystic | Drug: Lisinopril;Drug: Telmisartan;Drug: Placebo;Other: Standard Blood Pressure Control;Other: Low Blood Pressure Control | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Boehringer Ingelheim;Merck Sharp & Dohme Corp.;Polycystic Kidney Disease Foundation;University of Pittsburgh;Washington University School of Medicine | Completed | 15 Years | 64 Years | All | 558 | Phase 3 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 71 | NCT01885559 (ClinicalTrials.gov) | January 2006 | 17/6/2013 | HALT Progression of Polycystic Kidney Disease Study B | HALT Progression of Polycystic Kidney Disease Study B | Kidney, Polycystic | Drug: Lisinopril;Drug: Telmisartan;Drug: Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Boehringer Ingelheim;Merck Sharp & Dohme Corp.;Polycystic Kidney Disease Foundation;University of Pittsburgh;Washington University School of Medicine | Completed | 15 Years | 64 Years | All | 486 | Phase 3 | United States |
| 72 | NCT00413777 (ClinicalTrials.gov) | December 2005 | 18/12/2006 | Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) | A Phase 2, Multi-center, Open-label Study to Determine Long-term Safety, Tolerability and Efficacy of Split-dose Oral Regimens of Tolvaptan Tablets in a Range of 30 to 120 mg/d in Patients With Autosomal Dominant Polycystic Kidney Disease | Polycystic Kidney, Autosomal Dominant | Drug: Tolvaptan | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Pharmaceutical Co., Ltd. | Completed | 18 Years | N/A | All | 46 | Phase 2 | United States |